Antibodies are bioactive molecules and because of their binding properties have varied applications which range from medical diagnosis to therapy, the sensitive detection and removal of environmental contaminants, control of pathogens and industrial purification processes. (1)
In 1964 the generic term 'immunoglobulin' was internationally accepted by WHO for proteins of animal origin endowed with known antibody activity and for certain other proteins related to them by chemical structure. Immunoglobulins are synthesized by plasma cells and to some extent by lymphocytes. Immunoglobulins are glycoproteins, each molecule consisting of two pairs of polypeptide chains of different sizes. The smaller chains are light (L) chains (mol.wt-25,000) and larger chains are heavy (H) chains (mol.wt-50,000). Simplest antibody molecule has a 'Y' shape and consists of two H chains and two L chains. (2)
These antibodies are part of animal immune systems while plantibody is an antibody produced by genetically modified crops and are produced in plants by transforming them with antibody genes from animals. (3) A transgenic plant contains a gene or genes that have been artificially inserted.
The concept of using plants for recombinant antibodies (plantibodies) production (Figure 1) was first reported in 1983. (4) This combination of antibody and plant engineering, two rapidly advancing technologies, has resulted in the expression of a diversity of molecular forms in different plant species. (5)
Active immunization is the resistance developed in an individual as a result of an antigenic stimulus which is otherwise known as adaptive immunity. Passive immunity is the resistance transmitted to recipient in readymade form i.e., preformed antibodies are administered. There is no antigenic stimulus and recipient's immune system has no active role. The immunity is transient usually lasting only for days or weeks only till the passively transmitted antibodies are metabolized and eliminated. The main advantage of passive immunization is it acts immediately and can be employed in conditions requiring instant immunity. (1) Plantibodies confers passive immunity in an individual and can be used in the form of vaccines.
Transgenic plants expressing antigens are used as an inexpensive oral-vaccine production and delivery system so immunization is possible through consumption of an "edible vaccine" to provide passive immunization and disease prevention. (6) Genetically engineered plants and plant viruses are also used to produce vaccines against several human diseases for life threatening infections such as diphtheria, cholera and AIDS. (7)
Disadvantages of conventional culture systems:
For mammalian cell cultures:
* The high set-up and running costs,
* The limited opportunities for scale-up and
* The potential contamination of purified recombinant antibodies with human pathogens.
Bacterial fermentation systems:
* The yields of such products in bacteria are generally low because the proteins do not fold properly. (8)
The advantages of plants:
* The low production costs-requiring only traditional cultivation practices and labor.
* Large scale processing possible.
* Scale-up is rapid and efficient, requiring only the cultivation of additional land.
* Unlike transgenic animals, there is no need to maintain a founder herd, because transgenic plant lines can be stored as seed.
* Minimal risks of contamination with human pathogens. (9)
* The ability to introduce new or multiple transgenes by sexual crossing of plants.
* The avoidance of ethical problems associated with transgenic animals.
* Production size is flexible and easily adjustable to the needs of changing markets.
* The general eukaryotic protein synthesis pathway is conserved between plants and animals, so plants can efficiently fold and assemble full-size serum immunoglobulins and secretory IgA. (10, 11)
* Allergic reactions to plant protein glycans and other plant antigens.
* Plant and product contamination by mycotoxins, pesticides, herbicides and endogenous metabolites.
* Regulatory uncertainty, particularly for proteins requiring approval for human drug use. (12)
Studies using mice administered recombinant IgG isolated from plants showed that there were some differences in the glycan groups present on the recombinant antibody but neither the antibody nor the glycans were immunogenic. (13)
Choice of species:
A large number of different crops can be used to produce antibodies including tobacco (Nicotiana tabaccum and N. benthamiana), cereals (rice, wheat, maize), legumes (pea, soybean, alfalfa) and fruit and root crops (tomato, potato). (14)
Many factors should be considered before choosing the crop variety. Leafy crops like tobacco generally have the greatest biomass yields per hectare, because they can be cropped several times a year. Tomatoes also have high biomass yield, but production costs are increased.
Antibodies expressed in potato tubers and cereal grains are stable at room temperature for months or even years without loss of stability, while tobacco leaves must be dried or frozen prior to transport or storage to maintain the activity of recombinant proteins. However, extraction of proteins from seeds is more expensive than from watery tissue, such as tomatoes.
The presence of toxic metabolites such as alkaloids in tobacco presents a disadvantage, so edible plants lacking such compounds would be preferred expression hosts. Since most pharmaceutical antibodies will be produced by industry, the costs of production and processing in different crops will have to be evaluated very carefully. (9)
Six plant-derived antibodies have been developed as human therapeutics, two of which have reached phase II clinical trials. One of these is a full-length IgG specific for EpCAM (a marker of colorectal cancer) developed as the drug Avicidin by NeoRx and Monsanto. The five remaining antibodies are CaroRx, scFvT84.66, Anti-HSV, 38C13 and PIPP (antihCG). 
The other plant-derived antibody currently in phase II clinical trials is CaroRx, a chimeric secretory IgA/G produced in transgenic tobacco plants. The antibody is specific for the major adhesin of Streptococcus mutans, the organism responsible for dental caries in humans. Topical application following elimination of bacteria from the mouth helps to prevent recolonization by S. mutans and leads to the replacement of this pathogenic organism with harmless endogenous flora (Figure 2).
In a preliminary study of Caro Rx [TM], anti-S. mutans antibodies were orally administered to 84 human subjects. Upon the application of SA I/II, monoclonal antibodies prevented the colonization of artificially and naturally implanted S. mutans. In addition, protection from recolonization (with just 3 weeks of application) lasted for two years. (15)
Since IgG and secretory IgA may play a role in preventing bacterial adhesion to salivary glycoproteins or mucosal receptors, passive immunization and vaccine development against periodontal diseases has been attempted because of the success of passive immunization against S. mutans. (16)
The advances like plantibodies owing to their advantages are considered as breakthrough in techniques of molecular biology and may offer potential benefits for other fields like medicine in near future.
Received: January 14, 2014
Review Completed: February 12, 2014
Accepted: March 10, 2014
Available Online: July, 2014 (www.nacd.in)
(1.) Stoger E, Sack M, Fischer R, Christou P. Plantibodies: applications, advantages and bottlenecks. Curr Opin Biotechnol 2002; 13:161-166.
(2.) Ananthanarayan R and Paniker J: Antibodies-Immunoglobulins. Text book of Microbiology, 8th edition: 2009, Orient longman, 95-101.
(3.) Jain P, Pandey P, Jain D, Dwivedi P. Plantibody: An overview. Asian journal of Pharmacy and Life Science 2011; 1(1): 87-94.
(4.) Hiatt A, Cafferkey R, Bowdish K: Production of antibodies in transgenic plants. Nature 1989; 342:76-78.
(5.) Fischer R, Emans N. Molecular farming of pharmaceutical proteins. Transgenic Res 2000; 9:279-299.
(6.) Kusnadi AR, Nikolov ZL, Howard JA. Production of recombinant proteins in transgenic plants: practical considerations. Biotech Bioeng 1997; 56:473-484.
(7.) Moffat AS. Exploring transgenic plants as a new vaccine source. Science 1995; 268:658-660.
(8.) Chadd HE, Chamow SM. Therapeutic antibody expression technology. Curr Opin Biotechnol 2001; 12(2):188-194.
(9.) Fischer R, Twymanc RM, Schillberg S. Production of antibodies in plants and their use for global health. Vaccine 2003; 21:820-825.
(10.) Hiatt A, Cafferkey R, Bowdish K. Production of antibodies in transgenic plants. Nature 1989; 342(6245):76-78.
(11.) Ma JK, Hiatt A, Hein M, Vine ND, Wang F, Stabila P et al. Generation and assembly of secretory antibodies in plants. Science 1995; 268(5211):716-719.
(12.) Doran P.M. Foreign protein production in plant tissue cultures; Curr Opin Biotechnol 1999; 11: 199-204.
(13.) Chargelegue D, Vine N, Van Dolleweerd C, Drake PM, Ma J. A murine monoclonal antibody produced in transgenic plants with plant-specific glycans is not immunogenic in mice. Transgenic Res 2000; 9(3):187-194.
(14.) Schillberg S, Emans N, Fischer R. Antibody molecular farming in plants and plant cells. Phytochem Rev 2002; 1(1):45-54.
(15.) Larrick J.W., L. Yu, J. Chen, et al. Production of antibodies in transgenic plants; Research in Immunology 1998; 149(6): 603-608.
(16.) Malhotra R, Kapoor A, Grover V, Tuli AK. Periodontal vaccine. Indian J Dent Res 2011; 22:698-705.
Raja Babu P. , Tejaswi Ch. , Vidya Sagar S. , Satyanarayana D. .
 Prof and HOD  Post Graduate Student,  Associate Professor  Professor
Department of Periodontics, Kamineni Institute of Dental Sciences, Narketpally, Nalgonda (Dist), Telangana-508 254
Email for correspondence: email@example.com
|Printer friendly Cite/link Email Feedback|
|Author:||Babu P., Raja; Ch., Tejaswi; Sagar S., Vidya; D., Satyanarayana|
|Publication:||Indian Journal of Dental Advancements|
|Date:||Apr 1, 2014|
|Previous Article:||Oral malodor.|
|Next Article:||Root resection in maxillary molar with a retained fractured instrument and periodontal defect.|